Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel

References

• Thompson L D, Fisher S I, Chu W S, Nelson A, Abbondanzo S L. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol 2004; 121: 727–738
   PubMed Web of Science ®Google Scholar
• Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998; 16: 471–493
   PubMed Web of Science ®Google Scholar
• Bargou R C, Emmerich F, Krappmann D, Bommert K, Mapara M Y, Arnold W, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961–2969
   PubMed Web of Science ®Google Scholar
• Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943–953
   PubMed Web of Science ®Google Scholar
• Jarrett R F, MacKenzie J. Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Semin Hematol 1999; 36: 260–269
   PubMed Web of Science ®Google Scholar
• Glaser S L, Lin R J, Stewart S L, Ambinder R F, Jarrett R F, Brousset P, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70: 375–382
   PubMed Web of Science ®Google Scholar
• Andersson J. Epstein-Barr virus and Hodgkin's lymphoma. Herpes 2006; 13: 12–16
   PubMedGoogle Scholar
• Klein G. Perspectives in studies of human tumor viruses. Front Biosci 2002; 7: d268–d274
   Google Scholar
• Khan G, Lake A, Shield L, Freeland J, Andrew L, Alexander F E, et al. Phenotype and frequency of Epstein-Barr virus-infected cells in pretreatment blood samples from patients with Hodgkin lymphoma. Br J Haematol 2005; 129: 511–519
   PubMed Web of Science ®Google Scholar
• Devergne O, Hatzivassiliou E, Izumi K M, Kaye K M, Kleijnen M F, Kieff E, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol 1996; 16: 7098–7108
   PubMed Web of Science ®Google Scholar
• Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97: 2798–2807
   PubMed Web of Science ®Google Scholar
• Vlachaki M T, Ha C S, Hagemeister F B, Fuller L M, Rodriguez M A, Besa P C, et al. Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys 1997; 39: 609–616
   PubMed Web of Science ®Google Scholar
• Specht L, Gray R G, Clarke M J, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16: 830–843
   PubMed Web of Science ®Google Scholar
• Lavoie J C, Connors J M, Phillips G L, Reece D E, Barnett M J, Forrest D L, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473–1478
   PubMed Web of Science ®Google Scholar
• Josting A, Wolf J, Diehl V. Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol 2000; 12: 403–411
   PubMed Web of Science ®Google Scholar
• Advani R, Ai W Z, Horning S J. Management of advanced stage Hodgkin lymphoma. J Natl Compr Cancer Network 2006; 4: 241–247
   PubMedGoogle Scholar
• Connors J M, Noordijk E M, Horning S J. Hodgkin's lymphoma: basing the treatment on the evidence. Hematology (Am Soc Hematol Educ Program) 2001; 178–193
   PubMedGoogle Scholar
• Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
   PubMed Web of Science ®Google Scholar
• Glossmann J P, Josting A, Diehl V. New treatments for Hodgkin's disease. Curr Treat Options Oncol 2002; 3: 283–290
   PubMedGoogle Scholar
• Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T, et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000; 95: 3909–3914
   PubMed Web of Science ®Google Scholar
• Alexandrakis M G, Passam F H, Kyriakou D S, Bouros D. Pleural effusions in hematologic malignancies. Chest 2004; 125: 1546–1555
   PubMed Web of Science ®Google Scholar
• Haluska F G, Brufsky A M, Canellos G P. The cellular biology of the Reed-Sternberg cell. Blood 1994; 84: 1005–1019
   PubMed Web of Science ®Google Scholar
• Drexler H G, Leber B F, Norton J, Yaxley J, Tatsumi E, Hoffbrand A V, et al. Genotypes and immunophenotypes of Hodgkin's disease-derived cell lines. Leukemia 1988; 2: 371–376
   PubMed Web of Science ®Google Scholar
• Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, Miwa H, et al. Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 1986; 68: 285–292
   PubMed Web of Science ®Google Scholar
• Schaadt M, Diehl V, Stein H, Fonatsch C, Kirchner H H. Two neoplastic cell lines with unique features derived from Hodgkin's disease. Int J Cancer 1980; 26: 723–731
   PubMed Web of Science ®Google Scholar
• Diehl V, Kirchner H H, Burrichter H, Stein H, Fonatsch C, Gerdes J, et al. Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep 1982; 66: 615–632
   PubMedGoogle Scholar
• Kuppers R, Klein U, Schwering I, Distler V, Brauninger A, Cattoretti G, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 2003; 111: 529–537
   PubMed Web of Science ®Google Scholar
• Dukers D F, van Galen J C, Giroth C, Jansen P, Sewalt R G, Otte A P, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004; 164: 873–881
   PubMedGoogle Scholar
• Kuppers R, Schmitz R, Distler V, Renne C, Brauninger A, Hansmann M L. Pathogenesis of Hodgkin's lymphoma. Eur J Haematol 2005, Suppl: 26–33
   Google Scholar
• Kis L L, Nishikawa J, Takahara M, Nagy N, Matskova L, Takada K, et al. In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2. Int J Cancer 2005; 113: 937–945
   Google Scholar
• Kis L L, Nagy N, Klein G, Klein E. Expression of SH2D1A in five classical Hodgkin's disease-derived cell lines. Int J Cancer 2003; 104: 658–661
   PubMed Web of Science ®Google Scholar
• Markasz L, Stuber G, Flaberg E, Gustafsson Jernberg A, Eksborg S, Olah E, et al. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B cells. BMC Cancer 2006; 6: 265
   PubMed Web of Science ®Google Scholar
• Fogli S, Danesi R, Gennari A, Donati S, Conte P F, Del Tacca M. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol 2002; 13: 919–927
   PubMed Web of Science ®Google Scholar
• Andersson B, Andersson I, Beran M, Ehrsson H, Eksborg S. Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex. Cancer Chemother Pharmacol 1979; 2: 15–17
   PubMed Web of Science ®Google Scholar
• Toffoli G, Corona G, Cattarossi G, Boiocchi M, Di Gennaro G, Tirelli U, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol 2004; 15: 1805–1809
   PubMed Web of Science ®Google Scholar
• Kato Y, Nishimura S, Sakura N, Ueda K. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. Pediatr Int 2003; 45: 74–79
   PubMed Web of Science ®Google Scholar
• Gerrits C J, Schellens J H, Burris H, Eckardt J R, Planting A S, van der Burg M E, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 1999; 5: 69–75
   PubMed Web of Science ®Google Scholar
• Rischin D, Ackland S P, Smith J, Garg M B, Clarke S, Millward M J, et al. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. Ann Oncol 2002; 13: 1810–1818
   PubMed Web of Science ®Google Scholar
• Desai Z R, Van den Berg H W, Bridges J M, Shanks R G. Can severe vincristine neurotoxicity be prevented?. Cancer Chemother Pharmacol 1982; 8: 211–214
   PubMed Web of Science ®Google Scholar
• Bates S E, Bakke S, Kang M, Robey R W, Zhai S, Thambi P, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 2004; 10: 4724–4733
   PubMed Web of Science ®Google Scholar
• Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35–40
   PubMed Web of Science ®Google Scholar
• Ghazal-Aswad S, Calvert A H, Newell D R. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 1996; 37: 429–434
   PubMed Web of Science ®Google Scholar
• Graham M A, Lockwood G F, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000; 6: 1205–1218
   PubMed Web of Science ®Google Scholar
• Crews K R, Liu T, Rodriguez-Galindo C, Tan M, Meyer W H, Panetta J C, et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004; 100: 1724–1733
   PubMed Web of Science ®Google Scholar
• Chan G L, Erdmann G R, Gruber S A, Stock P, Chen S, Ascher N L, et al. Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. Eur J Clin Pharmacol 1989; 36: 265–271
   PubMed Web of Science ®Google Scholar
• Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Eriksson S, Juliusson G, et al. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res 1998; 4: 653–658
   PubMed Web of Science ®Google Scholar
• Casale F, Canaparo R, Serpe L, Muntoni E, Pepa C D, Costa M, et al. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 2004; 50: 173–179
   PubMed Web of Science ®Google Scholar
• Gruber A, Liliemark E, Tidefelt U, Paul C, Bjorkholm M, Peterson C, et al. Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia – relationship to treatment outcome and bone marrow toxicity. Leuk Res 1995; 19: 757–761
   PubMed Web of Science ®Google Scholar
• Peng Y M, Alberts D S, Chen H S, Mason N, Moon T E. Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. Br J Cancer 1980; 41: 644–647
   PubMed Web of Science ®Google Scholar
• Veal G J, Cole M, Errington J, Parry A, Hale J, Pearson A D, et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res 2005; 11: 5893–5899
   PubMed Web of Science ®Google Scholar
• Papandreou C N, Daliani D D, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108–2121
   PubMed Web of Science ®Google Scholar
• Xie H, Griskevicius L, Stahle L, Hassan Z, Yasar U, Rane A, et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 2006; 27: 54–61
   PubMed Web of Science ®Google Scholar
• Boddy A V, Yule S M, Wyllie R, Price L, Pearson A D, Idle J R. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol 1996; 38: 147–154
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Research Triangle Park N. Prescribing Information Leukeran®, http://us.gsk.com/products/assets/us_leukeran.pdf
   Google Scholar
• Ylikangas P, Mononen I. Serious neutropenia in ALL patients treated with l-asparaginase may be avoided by therapeutic monitoring of the enzyme activity in the circulation. Ther Drug Monit 2002; 24: 502–506
   PubMed Web of Science ®Google Scholar
• Yan J H, Ataga K, Kaul S, Olson J S, Grasela D M, Gothelf S, et al. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J Clin Pharmacol 2005; 45: 434–445
   PubMed Web of Science ®Google Scholar
• Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Therapeut 2007; 6: 644–654
   PubMed Web of Science ®Google Scholar
• Patterson L H, Murray G I. Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002; 8: 1335–1347
   PubMed Web of Science ®Google Scholar
• Kallab A M, Dainer P. A case of primary refractory Hodgkin's disease treated successfully with paclitaxel. Am J Hematol 1999; 60: 248
   PubMed Web of Science ®Google Scholar
• Younes A, Cabanillas F, McLaughlin P W, Hagemeister F B, Farber C, Sarris A, et al. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Ann Oncol 1996; 7: 1083–1085
   PubMed Web of Science ®Google Scholar
• Hopfinger G, Heinz R, Pfeilstocker M, Schlogl E, Waldner R, Pittermann E. Paclitaxel in the salvage treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Ann Oncol 1996; 7: 423–424
   PubMed Web of Science ®Google Scholar